Neurona Therapeutics

5 articles with Neurona Therapeutics

• Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders

  6/22/2021

  Neurona Therapeutics Inc. today announced the successful completion of a $41.5 million financing.

• Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)

  6/16/2021

  Neurona today announced the presentation of clinical trial plans and supporting preclinical data for its lead inhibitory neuron cell therapy candidate, NRTX-1001.

• Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal EpilepsyData presented at American Academy of Neuroscience (AAN) Annual Meeting

  4/19/2021

  Neurona Therapeutics , a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the presentation of preclinical data from its lead inhibitory neuron cell therapy program, which is being developed for the treatment of drug-resistant focal epilepsy.

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• UCSF Spinoff, Bay Area’s Neurona Therapeutics, Launches With $23.5 Million Series A Round

  12/4/2015